<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05072613</url>
  </required_header>
  <id_info>
    <org_study_id>548-21</org_study_id>
    <nct_id>NCT05072613</nct_id>
  </id_info>
  <brief_title>Monitoring Pregnant Women for Antimalarial Drug Resistance</brief_title>
  <acronym>MIRANDA</acronym>
  <official_title>Pregnant Women Attending Antenatal Care Services as a Sentinel Population for Antimalarial Drug Resistance Genetic Surveillance in Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kinshasa School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Sanger Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Annually, malaria affects an estimated 229 million people, causing 409,000 deaths (WHO 2019)&#xD;
      mostly in Africa. Despite a substantial decline in malaria-related maternal and child deaths&#xD;
      in recent years, progress in controlling malaria has been slower than anticipated and uneven&#xD;
      across countries. COVID-19-related disruption of malaria control activities will likely&#xD;
      further slow the pace and lead to an even greater burden in the near future.&#xD;
&#xD;
      One of the greatest challenges delaying progress in malaria elimination is antimalarial drug&#xD;
      resistance. Recent reports of the emergence of artemisinin-resistant parasites in parts of&#xD;
      Africa are the cause of even greater concern, since the loss of frontline treatment efficacy&#xD;
      could bring about a dramatic reversal of progress.&#xD;
&#xD;
      Large-scale genetic surveillance of Plasmodium is an effective tool for rapid detection of&#xD;
      changes in drug efficacy, enabling countries to switch to effective preventive and curative&#xD;
      treatments when necessary. The implementation of genetic surveillance has proven very&#xD;
      successful in small, low malaria burden countries. However, in large, high malaria burden&#xD;
      countries such implementation is operationally and economically more complex.&#xD;
&#xD;
      Screening pregnant women attending Antenatal Care (ANC) services can be a practical and&#xD;
      economical strategy for estimating malariometric parameters, with fewer limitations and&#xD;
      challenges than conventional survey methodologies in children. The present study aims to&#xD;
      demonstrate that this is also true for the genetic surveillance of antimalarial drug&#xD;
      resistance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the frequency of Plasmodium falciparum mutations associated with antimalarial drug resistance in the population of pregnant women with that of children.</measure>
    <time_frame>18 months</time_frame>
    <description>Plasmodium falciparum from infected individuals will be sequenced and the frequency of antimalarial drug resistance mutations in pregnant women will be compared with that of children.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the acceptability of the intervention</measure>
    <time_frame>12 months</time_frame>
    <description>Acceptability will be measured as: 1) the number of women who agree to be tested for malaria, over the number of women who attend the ANC service and 2) via a specially designed questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare malaria prevalence in pregnant women with that of in children throughout the year.</measure>
    <time_frame>12 months</time_frame>
    <description>Malaria prevalence will be measured by Rapid Diagnostic Test and standard malaria microscopy in both populations (pregnant women and children) for a period of 12 months and results compared.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">7080</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Pregnant women</arm_group_label>
    <description>Pregnant women attending Antenatal Care Services</description>
  </arm_group>
  <arm_group>
    <arm_group_label>School children</arm_group_label>
    <description>Children attending Primary Schools</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Malaria screening</intervention_name>
    <description>Participants are screened for malaria and a dried blood spot is collected from malaria positive cases</description>
    <arm_group_label>Pregnant women</arm_group_label>
    <arm_group_label>School children</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Dried Blood Spot. Only Plasmodium DNA will be analyzed.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women of all ages and in any trimester of pregnancy, and children &lt;14 years old&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnancy OR for children age &lt;14 years old and in primary school&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate (i.e., consent is not given by the participant for women or by&#xD;
             the parents in the case of children)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Caterina Fanello</last_name>
    <phone>+447900278768</phone>
    <email>caterina.fanello@ndm.ox.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie Onyamboko</last_name>
    <phone>+243990024201</phone>
    <email>marie.onyamboko@unikin.ac.cd</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kinshasa Medical Oxford Research Unit</name>
      <address>
        <city>Kinsasa</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <contact>
      <last_name>Caterina Fanello</last_name>
      <email>caterina.fanello@ndm.ox.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Marie Onyamboko</last_name>
      <email>marie.onyamboko@unikin.ac.cd</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
  </location_countries>
  <reference>
    <citation>Brunner NC, Chacky F, Mandike R, Mohamed A, Runge M, Thawer SG, Ross A, Vounatsou P, Lengeler C, Molteni F, Hetzel MW. The potential of pregnant women as a sentinel population for malaria surveillance. Malar J. 2019 Nov 21;18(1):370. doi: 10.1186/s12936-019-2999-0.</citation>
    <PMID>31752889</PMID>
  </reference>
  <reference>
    <citation>Mayor A, Men√©ndez C, Walker PGT. Targeting Pregnant Women for Malaria Surveillance. Trends Parasitol. 2019 Sep;35(9):677-686. doi: 10.1016/j.pt.2019.07.005. Epub 2019 Aug 5. Review.</citation>
    <PMID>31395496</PMID>
  </reference>
  <reference>
    <citation>van Eijk AM, Hill J, Noor AM, Snow RW, ter Kuile FO. Prevalence of malaria infection in pregnant women compared with children for tracking malaria transmission in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2015 Oct;3(10):e617-28. doi: 10.1016/S2214-109X(15)00049-2. Epub 2015 Aug 19. Review.</citation>
    <PMID>26296450</PMID>
  </reference>
  <reference>
    <citation>Willilo RA, Molteni F, Mandike R, Mugalura FE, Mutafungwa A, Thadeo A, Benedictor E, Kafuko JM, Kaspar N, Ramsan MM, Mwaipape O, McElroy PD, Gutman J, Colaco R, Reithinger R, Ngondi JM. Pregnant women and infants as sentinel populations to monitor prevalence of malaria: results of pilot study in Lake Zone of Tanzania. Malar J. 2016 Jul 29;15(1):392. doi: 10.1186/s12936-016-1441-0.</citation>
    <PMID>27473039</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antimalarial Drug Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

